Leukemia Cell Articles & Analysis
13 news found
Rebecca holds a master’s degree in biomedicine and has since conducted research for several years at Lund University in leukemia, where she used single-cell methods to study treatment-resistant leukemic stem cells. ...
” Business Highlights & Clinical Updates Provided update from the ongoing Phase 1 clinical trial of INB-100 in patients with leukemia who are undergoing haploidentical stem cell transplantation. All three high-risk AML patients from the first cohort continued to demonstrate durable morphologic CR and remained progression-free and alive for more than ...
(Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced positive early data from the ongoing Phase 1 trial evaluating INB-100, an allogeneic gamma-delta T cell therapy, in patients with high-risk acute myeloid leukemia (AML) ...
“The Dunbar CAR T-Cell Program has a superb facility designed specifically to advance the development of promising T-cell therapies. ...
This program is an allogeneic, or donor-derived, gamma-delta T cell therapeutic candidate in development for patients with high-risk leukemias undergoing haploidentical hematopoietic stem cell transplant (HSCT). ...
European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural killer (NK) cells Patent portfolio broadly covers chemotherapy resistant engineering of innate immune cells for cellular therapy, providing the basis for IN8bio’s Drug ...
“My career has always been directed toward advancing novel disruptive therapies. Gamma-delta T cells are the prototype of ‘unconventional’ T cells, having both innate and adaptive immune properties. ...
Fehniger, MD, PhD, Professor of Medicine, Washington University School of Medicine, an internationally recognized leader in natural killer (NK) cell immunotherapy, stem cell transplantation and lymphomas Prof. Dr. ...
Senti Bio’s oncology pipeline is primarily focused on three preclinical-stage programs: SENTI-202, a Logic Gated (OR+NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells while sparing the healthy bone marrow; SENTI-301, a regulatable Multi-Armed off-the-shelf CAR-NK cell ...
Senti Bio is developing next-generation cell and gene therapies engineered with gene circuits, which are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their respective cellular environments. ...
SENTI-202 oral presentation details systematic optimization of Logic Gating Gene Circuit technology in allogeneic CAR-NK cells to more precisely target tumor cells in acute myeloid leukemia, while sparing healthy cells SENTI-301 poster presentation highlights optimization of Multi-Arming and Regulator Dial Gene Circuits to ...
Lentiviruses are widely used as a tool to deliver genes of interest to cells. In this case, the lentivirus transduces (or inserts) a group of genes to a patient’s T cells (immune cells), which turn the T cells into cancer-killing CAR-T cells targeting LGR5, a cancer stem cell marker found ...
The successes observed with hematologic malignancies have revolutionized anticancer therapy, providing a potentially curative option for patients with pre-B cell acute lymphoblastic leukemia (ALL) or B cell lymphomas. There is a substantial effort being made towards expanding the impact of this line of therapy to other tumor types, mainly solid ...